Jean-Charles Fruchart

Author PubWeight™ 204.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009 35.24
2 Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 15.18
3 HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007 6.31
4 Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006 5.67
5 Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006 3.48
6 Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006 3.37
7 The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006 2.38
8 Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005 2.32
9 Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004 2.16
10 Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol 2006 2.15
11 Increased ABCA1 activity protects against atherosclerosis. J Clin Invest 2002 2.13
12 Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. Atherosclerosis 2003 2.02
13 C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 2003 1.99
14 Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004 1.98
15 The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem 2005 1.85
16 Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 2002 1.80
17 Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007 1.79
18 Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003 1.78
19 The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation. J Biol Chem 2003 1.76
20 Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties. Circ Res 2004 1.72
21 Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription. J Lipid Res 2002 1.71
22 PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 2005 1.68
23 Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol Endocrinol 2002 1.63
24 Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha. Arterioscler Thromb Vasc Biol 2005 1.63
25 Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004 1.63
26 Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004 1.63
27 Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003 1.60
28 PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest 2005 1.58
29 Perilipin, a potential substitute for adipophilin in triglyceride storage in human macrophages. Atherosclerosis 2006 1.54
30 Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 2003 1.54
31 Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 2004 1.53
32 Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis. Arterioscler Thromb Vasc Biol 2004 1.48
33 Implications of emerging risk factors for therapeutic intervention. Nutr Metab Cardiovasc Dis 2005 1.43
34 Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002 1.41
35 Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab 2007 1.41
36 Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest 2005 1.37
37 Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 2002 1.36
38 Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. Arterioscler Thromb Vasc Biol 2009 1.36
39 Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 2003 1.31
40 Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol 2006 1.26
41 Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004 1.25
42 The role of PPARs in atherosclerosis. Trends Mol Med 2002 1.22
43 Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. J Biol Chem 2002 1.22
44 Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Lett 2005 1.21
45 Both hepatic and extrahepatic ABCA1 have discrete and essential functions in the maintenance of plasma high-density lipoprotein cholesterol levels in vivo. Circulation 2006 1.20
46 Combination lipid therapy in type 2 diabetes. N Engl J Med 2010 1.20
47 Plasma cystatin-C and development of coronary heart disease: The PRIME Study. Atherosclerosis 2005 1.19
48 Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol 2004 1.16
49 PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 2006 1.16
50 Transcriptional regulation of human Rev-erbalpha gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor alpha. J Biol Chem 2002 1.14
51 Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 2006 1.13
52 Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol Endocrinol 2008 1.12
53 The nuclear receptor Rev-erbalpha is a liver X receptor (LXR) target gene driving a negative feedback loop on select LXR-induced pathways in human macrophages. Mol Endocrinol 2008 1.11
54 FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 2003 1.11
55 PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann N Y Acad Sci 2002 1.10
56 Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem Biophys Res Commun 2006 1.09
57 Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 2002 1.09
58 DNA binding-independent induction of IkappaBalpha gene transcription by PPARalpha. Mol Endocrinol 2002 1.07
59 The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. Mol Endocrinol 2004 1.07
60 Adipophilin increases triglyceride storage in human macrophages by stimulation of biosynthesis and inhibition of beta-oxidation. FEBS J 2006 1.06
61 Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis 2002 1.06
62 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem 2003 1.05
63 Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ Res 2007 1.05
64 The farnesoid X receptor induces very low density lipoprotein receptor gene expression. FEBS Lett 2004 1.04
65 Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. Curr Opin Pharmacol 2005 1.03
66 Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol 2005 1.02
67 Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 2006 1.02
68 Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 2004 1.01
69 Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J Biol Chem 2003 1.00
70 Paullinia pinnata extracts rich in polyphenols promote vascular relaxation via endothelium-dependent mechanisms. J Cardiovasc Pharmacol 2006 0.99
71 Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins? Ann Med 2006 0.99
72 Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function. Curr Opin Lipidol 2003 0.98
73 Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4alpha. Mol Pharmacol 2004 0.94
74 Analysis of apolipoprotein A5, c3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol 2004 0.92
75 Molecular mechanism of the blockade of plasma cholesteryl ester transfer protein by its physiological inhibitor apolipoprotein CI. J Biol Chem 2005 0.92
76 The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol 2006 0.92
77 Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. Expert Opin Emerg Drugs 2006 0.92
78 The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c. J Biol Chem 2004 0.92
79 The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004 0.91
80 [Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control]. J Soc Biol 2002 0.91
81 FXR-deficiency confers increased susceptibility to torpor. FEBS Lett 2007 0.91
82 Different ways to regulate the PPARalpha stability. Biochem Biophys Res Commun 2004 0.91
83 Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes. Trends Endocrinol Metab 2004 0.88
84 Postprandial leptin response to carbohydrate and fat meals in obese women. J Am Coll Nutr 2003 0.88
85 Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome. Clin Chem Lab Med 2007 0.88
86 Farnesoid X receptor represses hepatic lipase gene expression. J Lipid Res 2004 0.87
87 Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia. Circ Res 2008 0.87
88 The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy. J Cardiovasc Pharmacol 2007 0.87
89 Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line. Biochim Biophys Acta 2003 0.87
90 Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia 2005 0.86
91 Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. Biochimie 2005 0.86
92 Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians. Ther Adv Chronic Dis 2011 0.85
93 Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity. J Med Chem 2005 0.85
94 Scavenger receptor BI (SR-BI) mediates a higher selective cholesteryl ester uptake from LpA-I compared with LpA-I:A-II lipoprotein particles. Atherosclerosis 2003 0.85
95 Extracellular human thioredoxin-1 inhibits lipopolysaccharide-induced interleukin-1beta expression in human monocyte-derived macrophages. J Biol Chem 2005 0.85
96 Liver X receptor activation induces the uptake of cholesteryl esters from high density lipoproteins in primary human macrophages. Arterioscler Thromb Vasc Biol 2008 0.83
97 Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta. Biochem Biophys Res Commun 2002 0.82
98 Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. Trends Pharmacol Sci 2003 0.82
99 Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia. Arch Med Res 2004 0.82
100 Glucose regulates LXRalpha subcellular localization and function in rat pancreatic beta-cells. Cell Res 2006 0.82
101 Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression. J Cardiovasc Pharmacol 2005 0.82
102 Expression and secretion of human apolipoprotein A-I in the heart. FEBS Lett 2004 0.82
103 Apolipoprotein E knockout mice over-expressing human tissue inhibitor of metalloproteinase 1 are protected against aneurysm formation but not against atherosclerotic plaque development. J Vasc Res 2006 0.81
104 Diabetes mellitus worsens antioxidant status in patients with chronic pancreatitis. Am J Clin Nutr 2005 0.81
105 The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activity. Diabetes Care 2007 0.81
106 Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism. J Cardiovasc Pharmacol 2004 0.80
107 Lipid free apolipoprotein E binds to the class B Type I scavenger receptor I (SR-BI) and enhances cholesteryl ester uptake from lipoproteins. J Biol Chem 2002 0.80
108 Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 2004 0.80
109 PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis. Semin Arthritis Rheum 2007 0.80
110 Complete functional rescue of the ABCA1-/- mouse by human BAC transgenesis. J Lipid Res 2005 0.80
111 Enhanced cholesterol efflux promotion in well-trained soccer players. Metabolism 2004 0.80
112 Glucose regulates the expression of the apolipoprotein A5 gene. J Mol Biol 2008 0.79
113 Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. Bioorg Med Chem Lett 2007 0.78
114 Liver X receptors: new players in atherogenesis? Curr Opin Lipidol 2003 0.78
115 Natural phenylpropanoids protect endothelial cells against oxidized LDL-induced cytotoxicity. Planta Med 2003 0.78
116 [The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome]. Endocrinol Nutr 2011 0.78
117 Characterization of a new mouse model for human apolipoprotein A-I/C-III/A-IV deficiency. J Lipid Res 2006 0.78
118 Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene. Clin Chim Acta 2006 0.77
119 SR-BI does not require raft/caveola localisation for cholesteryl ester selective uptake in the human adrenal cell line NCI-H295R. Biochim Biophys Acta 2003 0.77
120 Early-glycation of apolipoprotein E: effect on its binding to LDL receptor, scavenger receptor A and heparan sulfates. Biochim Biophys Acta 2002 0.77
121 [Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development]. Med Sci (Paris) 2003 0.77
122 Natural phenylpropanoids inhibit lipoprotein-induced endothelin-1 secretion by endothelial cells. J Pharm Pharmacol 2004 0.77
123 HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. Clin Sci (Lond) 2002 0.76
124 [PPAR gamma: a major nuclear receptor in adipogenesis]. Med Sci (Paris) 2003 0.76
125 The plasma and lipoprotein triglyceride postprandial response to a carbohydrate tolerance test differs in lean and massively obese normolipidemic women. J Nutr 2002 0.76
126 Retinoic acid receptor-related orphan receptor alpha as a therapeutic target in the treatment of dyslipidemia and atherosclerosis. Drug News Perspect 2006 0.76
127 Melatonin related compounds inhibit lipid peroxidation during copper or free radical-induced LDL oxidation. J Pineal Res 2002 0.75
128 Apolipoprotein A-V modulates insulin secretion in pancreatic beta-cells through its interaction with midkine. Cell Physiol Biochem 2009 0.75
129 Human free apolipoprotein A-I and artificial pre-beta-high-density lipoprotein inhibit eNOS activity and NO release. Biochim Biophys Acta 2004 0.75
130 [4-(2H-1,2,3-benzotriazol-2-yl)phenoxy]alkanoic acids as agonists of peroxisome proliferator-activated receptors (PPARs). Chem Biodivers 2006 0.75
131 Genetically-engineered animals as research models for atherosclerosis: their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders. Front Biosci 2007 0.75